Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Next Previous
X
Search
Trial Profile

Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GO-NICE
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 15 Jun 2019 Results of a post-hoc analysis assessing the effectiveness of Golimumab used as first, second, or at least third biologic agent in RA, PsA and AS (n=1458), presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results (n=1483) investigating the direct and indirect costs of healthcare utilization and sick leave after starting a treatment with golimumab presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Mar 2019 Results of post-hoc subgroup analysis published in The Journal of Rheumatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top